Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Bellicum Pharmaceuticals (BLCM) stocks in Canada

Learn how to easily invest in Bellicum Pharmaceuticals stocks.

Bellicum Pharmaceuticals is a biotechnology business based in the US. Bellicum Pharmaceuticals stocks (BLCM.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.05 – a decrease of 0.68% over the previous week. Bellicum Pharmaceuticals employs 7 staff and has a trailing 12-month revenue of around $6.2 million.

How to buy shares in Bellicum Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – BLCM – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Bellicum Pharmaceuticals stock price (NASDAQ:BLCM)

Use our graph to track the performance of BLCM stocks over time.

Bellicum Pharmaceuticals shares at a glance

Information last updated 2022-01-17.
Latest market close$1.45
52-week range$1.43 - $8.15
50-day moving average $1.72
200-day moving average $2.69
Wall St. target price$4.50
PE ratio 2.1283
Dividend yield N/A (0%)
Earnings per share (TTM) $0.69

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99 - $9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy Bellicum Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Bellicum Pharmaceuticals price performance over time

Historical closes compared with the close of $1.45 from 2022-01-21

1 week (2022-01-14) -0.68%
1 month (2021-12-20) -15.20%
3 months (2021-10-19) -35.84%
6 months (2021-07-22) -51.51%
1 year (2021-01-22) -65.23%
2 years (2020-01-22) -31.92%
3 years (2019-01-22) 3.23
5 years (2017-01-20) 12.55

Is Bellicum Pharmaceuticals under- or over-valued?

Valuing Bellicum Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bellicum Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Bellicum Pharmaceuticals's P/E ratio

Bellicum Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 2x. In other words, Bellicum Pharmaceuticals shares trade at around 2x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Bellicum Pharmaceuticals financials

Revenue TTM $6.2 million
Gross profit TTM $-38,552,000
Return on assets TTM -46.66%
Return on equity TTM -378.68%
Profit margin 105.6%
Book value $0.25
Market capitalisation $12.3 million

TTM: trailing 12 months

Bellicum Pharmaceuticals share dividends

We're not expecting Bellicum Pharmaceuticals to pay a dividend over the next 12 months.

Have Bellicum Pharmaceuticals's shares ever split?

Bellicum Pharmaceuticals's shares were split on a 1:10 basis on 6 February 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Bellicum Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Bellicum Pharmaceuticals shares which in turn could have impacted Bellicum Pharmaceuticals's share price.

Bellicum Pharmaceuticals share price volatility

Over the last 12 months, Bellicum Pharmaceuticals's shares have ranged in value from as little as $1.43 up to $8.15. A popular way to gauge a stock's volatility is its "beta".

BLCM.US volatility(beta: 1.49)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bellicum Pharmaceuticals's is 1.4866. This would suggest that Bellicum Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Bellicum Pharmaceuticals overview

Bellicum Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes when administered after hematopoietic stem cell transplantation in the treatment of hematologic malignancies and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc. ; BioVec Pharma, Inc. ; ARIAD Pharmaceuticals, Inc.

Stocks similar to Bellicum Pharmaceuticals

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site